Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 293-299

  Ren, Clement L ^a   Konstan, Michael W ^b   Yegin, Ashley ^c   Rasouliyan, Lawrence ^d   Trzaskoma, Benjamin ^c   Morgan, Wayne J ^e   Regelmann, Warren ^f  

^a UNIVERSITY OF ROCHESTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d ICON Late Phase and Outcomes Research   (United States)

^e Arizona Respiratory   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antibiotic resistance; Epidemiology; FEV1; Lung infections; Spirometry

Indexed keywords

AMIKACIN; GENTAMICIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; SPIROMETRY;

ADRENAL CORTEX HORMONES; ADULT; ANTI-BACTERIAL AGENTS; CHILD; COHORT STUDIES; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; SPIROMETRY; YOUNG ADULT;

EID: 84862487763     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.02.005     Document Type: Article

References (25)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis 1. Am J Respir Crit Care Med 2003, 168:918-951.
2. Merlo C.A., Boyle M.P., Diener-West M., Marshall B.C., Goss C.H., Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007, 132:562-568.
3. Block J.K., Vandemheen K.L., Tullis E., Fergusson D., Doucette S., Haase D., et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006, 61:969-974.
4. Davies G., McShane D., Davies J.C., Bush A. Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation. Pediatr Pulmonol 2003, 35:253-256.
5. Lechtzin N., John M., Irizarry R., Merlo C., Diette G.B., Boyle M.P. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006, 73:27-33.
6. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151(134-139):139 e131.
7. Sanders D.B., Bittner R.C., Rosenfeld M., Redding G.J., Goss C.H. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011, 46:393-400.
8. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005, 366:463-471.
9. Etherington C., Hall M., Conway S., Peckham D., Denton M. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Antimicrob Chemother 2008, 61:425-427.
10. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502.
11. Morgan W.J., Butler S.M., Johnson C.A., Colin A.A., FitzSimmons S.C., Geller D.E., et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999, 28:231-241.
12. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
13. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
14. Johnson C., Butler S.M., Konstan M.W., Morgan W., Wohl M.E. Factors influencing outcomes in cystic fibrosis: a center-based analysis 1. Chest 2003, 123:20-27.
15. Emerson J., McNamara S., Buccat A.M., Worrell K., Burns J.L. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010, 45:363-370.
16. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., Barmeier H., et al. Prospective evaluation of emerging bacteria in cystic fibrosis 1. J Cyst Fibros 2005, 4:41-48.
17. Saiman L., Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003, 31:S1-S62.
18. Cystic fibrosis foundation patient registry annual data report 2008, Cystic Fibrosis Foundation, Bethesda, MD.
19. Dasenbrook E.C., Merlo C.A., Diener-West M., Lechtzin N., Boyle M.P. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
20. Goss C.H., Otto K., Aitken M.L., Rubenfeld G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356-361.
21. Nadesalingam K., Conway S.P., Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis 3. J Cyst Fibros 2005, 4:49-52.
22. Sawicki G.S., Rasouliyan L., Pasta D.J., Regelmann W.E., Wagener J.S., Waltz D.A., et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008, 43:1117-1123.
23. Kalish L.A., Waltz D.A., Dovey M., Potter-Bynoe G., McAdam A.J., Lipuma J.J., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006, 173:421-425.
24. Goss C.H., Mayer-Hamblett N., Aitken M.L., Rubenfeld G.D., Ramsey B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955-959.
25. Shreve M.R., Butler S., Kaplowitz H.J., Rabin H.R., Stokes D., Light M., et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol 1999, 37:753-757.